Document Type
Article
Publication Date
4-18-2013
Abstract
Agonists of the transmembrane intestinal receptor guanylyl cyclase C (GCC) have recently attracted interest as promising human therapeutics. Peptide ligands that can specifically induce GCC signaling in the intestine include endogenous hormones guanylin and uroguanylin, diarrheagenic bacterial enterotoxins (ST), and synthetic drugs linaclotide, plecanatide, and SP-333. These agonists bind to GCC at intestinal epithelial surfaces and activate the receptor's intracellular catalytic domain, an event initiating discrete biological responses upon conversion of guanosine-5'-triphosphate to cyclic guanosine monophosphate. A principal action of GCC agonists in the colon is the promotion of mucosal homeostasis and its dependent barrier function. Herein, GCC agonists are being developed as new medications to treat inflammatory bowel diseases, pathological conditions characterized by mucosal barrier hyperpermeability, abnormal immune reactions, and chronic local inflammation. This review will present important concepts underlying the pharmacology and therapeutic utility of GCC agonists for patients with ulcerative colitis, one of the most prevalent inflammatory bowel disease disorders.
Recommended Citation
Pitari, Giovanni M, "Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis." (2013). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 48.
https://jdc.jefferson.edu/petfp/48
PubMed ID
23637522
Comments
This article has been peer reviewed. It was published in: Drug Design, Development and Therapy.
Volume 7, 18 April 2013, Pages 351-360.
The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634396/ DOI: 10.2147/DDDT.S32252
© 2013 Pitari, publisher and licensee Dove Medical Press Ltd.